Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Bret R. Rutherford, M.D.
WARNING LETTER
•Bret R. Rutherford, M.D.•January 10, 2023

Bret R. Rutherford, M.D. – FDA Warning Letter, Jan 10, 2023

Record Details

The FDA issued a Warning Letter to Dr. Rutherford following an inspection from December 19, 2022, to January 10, 2023, under the Bioresearch Monitoring Program. The inspection revealed that Dr. Rutherford failed to ensure clinical investigations for Protocols (b)(4) and (b)(4) were conducted according to the investigational plan, specifically regarding subject eligibility criteria [21 CFR 312.60].

The protocols required exclusion of subjects on current or recent (within 4 weeks) antidepressants, antipsychotics, or mood stabilizers, or a specific tapering and washout period (5 elimination half-lives or 2 weeks, whichever is longer) for those on antidepressants who had not responded to adequate trials. Numerous subjects in both protocols were randomized and received study drug without completing the required medication tapering and washout period.

While Dr. Rutherford acknowledged the oversight and stated that the medication-free period was primarily for data validity, the FDA noted that failure to adhere to this requirement significantly impacted data integrity and subject safety, as ineligible subjects were enrolled.

Corrective actions included reviewing involved subjects for harm (none found), closing Protocol (b)(4) and initiating closure for Protocol (b)(4), suspending enrollment for Protocol (b)(4) in September 2021, and withdrawing the associated IND in January 2023. No further research under these protocols will be conducted, and data will not be used

Company
Bret R. Rutherford, M.D.
Inspection date
January 10, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • David C. Burrow (Director )
View Company Profile

ID · 6f478d15-4c3d-4c45-a60e-f1b47fc54ee8

Violation Codes2
21 CFR 31221 CFR 312.60

Full citation text and observation details available on the Dashboard.

Other documents for Bret R. Rutherford, M.D.
  • 483 - 2023-01-10January 10, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bret R. Rutherford, M.D.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.